Literature DB >> 26405612

Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).

Sylvia Adams1, Lori J Goldstein2, Joseph A Sparano3, Sandra Demaria1, Sunil S Badve4.   

Abstract

Upon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.

Entities:  

Keywords:  TNBC; biomarker; breast cancer; tumor infiltrating lymphocytes

Year:  2015        PMID： 26405612      PMCID： PMC4570112          DOI： 10.4161/2162402X.2014.985930

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer.

Authors:  Carsten Denkert
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

2.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

3.  PD-L1 expression in triple-negative breast cancer.

Authors:  Elizabeth A Mittendorf; Anne V Philips; Funda Meric-Bernstam; Na Qiao; Yun Wu; Susan Harrington; Xiaoping Su; Ying Wang; Ana M Gonzalez-Angulo; Argun Akcakanat; Akhil Chawla; Michael Curran; Patrick Hwu; Padmanee Sharma; Jennifer K Litton; Jeffrey J Molldrem; Gheath Alatrash
Journal:  Cancer Immunol Res       Date:  2014-01-10       Impact factor: 11.151

4.  Leukocyte composition of human breast cancer.

Authors:  Brian Ruffell; Alfred Au; Hope S Rugo; Laura J Esserman; E Shelley Hwang; Lisa M Coussens
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

5.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Authors:  Sherene Loi; Nicolas Sirtaine; Fanny Piette; Roberto Salgado; Giuseppe Viale; Françoise Van Eenoo; Ghizlane Rouas; Prudence Francis; John P A Crown; Erika Hitre; Evandro de Azambuja; Emmanuel Quinaux; Angelo Di Leo; Stefan Michiels; Martine J Piccart; Christos Sotiriou
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

Review 6.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Authors:  Jérôme Galon; Helen K Angell; Davide Bedognetti; Francesco M Marincola
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 7.  Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.

Authors:  Thomas F Gajewski; Seng-Ryong Woo; Yuanyuan Zha; Robbert Spaapen; Yan Zheng; Leticia Corrales; Stefani Spranger
Journal:  Curr Opin Immunol       Date:  2013-04-08       Impact factor: 7.486

8.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

Authors:  Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

9.  Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.

Authors:  Paul F Robbins; Yong-Chen Lu; Mona El-Gamil; Yong F Li; Colin Gross; Jared Gartner; Jimmy C Lin; Jamie K Teer; Paul Cliften; Eric Tycksen; Yardena Samuels; Steven A Rosenberg
Journal:  Nat Med       Date:  2013-05-05       Impact factor: 53.440

10.  Clonal evolution in breast cancer revealed by single nucleus genome sequencing.

Authors:  Yong Wang; Jill Waters; Marco L Leung; Anna Unruh; Whijae Roh; Xiuqing Shi; Ken Chen; Paul Scheet; Selina Vattathil; Han Liang; Asha Multani; Hong Zhang; Rui Zhao; Franziska Michor; Funda Meric-Bernstam; Nicholas E Navin
Journal:  Nature       Date:  2014-07-30       Impact factor: 49.962
  10 in total
  28 in total

1.  Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.

Authors:  Simone Borgoni; Andrea Iannello; Santina Cutrupi; Paola Allavena; Maurizio D'Incalci; Francesco Novelli; Paola Cappello
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

Review 2.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

3.  Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.

Authors:  Michael J Campbell; Frederick Baehner; Tess O'Meara; Ekene Ojukwu; Booyeon Han; Rita Mukhtar; Vickram Tandon; Max Endicott; Zelos Zhu; Jasmine Wong; Gregor Krings; Alfred Au; Joe W Gray; Laura Esserman
Journal:  Breast Cancer Res Treat       Date:  2016-10-26       Impact factor: 4.872

4.  Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.

Authors:  Yuan Yuan; Jin Sun Lee; Susan E Yost; Sierra Min Li; Paul H Frankel; Christopher Ruel; Daniel Schmolze; Kim Robinson; Aileen Tang; Norma Martinez; Daphne Stewart; James Waisman; Laura Kruper; Veronica Jones; Andrea Menicucci; Sahra Uygun; Erin Yoder; Bastiaan van der Baan; John H Yim; Christina Yeon; George Somlo; Joanne Mortimer
Journal:  Oncologist       Date:  2020-11-08

5.  Pretreatment lymphocyte to monocyte ratio as a predictor of prognosis in patients with early-stage triple-negative breast cancer.

Authors:  Juanjuan He; Pengwei Lv; Xue Yang; Yanli Chen; Chao Liu; Xinguang Qiu
Journal:  Tumour Biol       Date:  2016-01-13

6.  Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.

Authors:  Gilda Schmidt; Christoph Gerlinger; Ingolf Juhasz-Böss; Elmar Stickeler; Achim Rody; Cornelia Liedtke; Pauline Wimberger; Theresa Link; Eberhard Müller; Tanja Fehm; Manuela Abel; Stefan Stein; Rainer Bohle; Jan Endrikat; Erich-Franz Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-23       Impact factor: 4.553

7.  Identification of candidate genes associated with triple negative breast cancer.

Authors:  Audrey Player; Nissi Abraham; Kayla Burrell; Iria Ondo Bengone; Anthony Harris; Lisa Nunez; Telisa Willaims; Sharon Kwende; Wiley Walls
Journal:  Genes Cancer       Date:  2017-07

Review 8.  Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.

Authors:  Elisa Agostinetto; Daniel Eiger; Kevin Punie; Evandro de Azambuja
Journal:  Curr Oncol Rep       Date:  2021-03-24       Impact factor: 5.075

9.  Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1.

Authors:  Jamaal L James; Justin M Balko
Journal:  Curr Breast Cancer Rep       Date:  2019-11-11

10.  TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes.

Authors:  Franziska Würfel; Ramona Erber; Hanna Huebner; Alexander Hein; Michael P Lux; Sebastian Jud; Anita Kremer; Hannah Kranich; Andreas Mackensen; Lothar Häberle; Carolin C Hack; Claudia Rauh; Marius Wunderle; Paul Gaß; Shahrooz Rabizadeh; Anna-Lisa Brandl; Hanna Langemann; Bernhard Volz; Naiba Nabieva; Rüdiger Schulz-Wendtland; Diana Dudziak; Matthias W Beckmann; Arndt Hartmann; Peter A Fasching; Matthias Rübner
Journal:  Breast Care (Basel)       Date:  2018-02-15       Impact factor: 2.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.